Resyca, Recipharm’s joint venture with Medspray, has boarded its first pharmaceutical customer on the soft mist inhaler (SMI) platform. An agreement has been signed involving milestones and royalties for exclusivity on the specific drug product.
 
The SMI platform consists of a portable disposable nebulizer featuring a microspray nozzle developed by spray specialist Medspray, which is designed to generate a near-monodisperse aerosol with a high lung dose. The SMI device is purely mechanical, allowing simple aqueous solutions to be used without the need for any propellants. As a result, it can substantially simplify the formulation development process for new inhalation products.
 
The device platform consists of both prefilled syringe inhaler (PFSI) devices and clinical devices that can be filled on the spot, speeding up clinical investigations. Development, manufacture, filling, assembly and packaging take place within Recipharm Group.
 
“The SMI platform has been designed specially to deliver a true turn-key device solution to the customer that requires minimal customization and simplifies the formulation process,” said Resyca’s Wilbur de Kruijf. “As a result, we can minimize device and drug development timeframes in collaboration with Recipharm, allowing our customers to focus on clinical research.”